DNTH
Dianthus Therapeutics, Inc.
Biotechnology
Market Cap$3.19B
5Y Perf.-39.1%
Build Your Comparison
Side-by-side financial analysisDNTH
BCAB
Try popular comparisons:
Stock Comparison
DNTH vs BCAB
Revenue, margins, valuation, and 5-year total return — side by side.
BCAB
BioAtla, Inc.
Biotechnology
Market Cap$4M
5Y Perf.-99.8%
DNTH vs BCAB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  DNTH |  BCAB |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $3.19B | $4M |
| Revenue (TTM) | $1M | $2M |
| Net Income (TTM) | $-11M | $-51M |
| Gross Margin | 94.3% | 106.0% |
| Operating Margin | -143.2% | -25.2% |
| Total Debt | $1M | $6M |
| Cash & Equiv. | $51M | $7M |
DNTH vs BCAB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
DNTH
BCAB
| Stock | Dec 20 | Jun 26 | Return |
|---|---|---|---|
| Dianthus Therapeuti… (DNTH) | 100 | 60.9 | -39.1% |
| BioAtla, Inc. (BCAB) | 100 | 0.2 | -99.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DNTH vs BCAB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: DNTH leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. BioAtla, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
🥇DNTH emerged as the overall leader. Track its performance:
DNTH
Dianthus Therapeutics, Inc.
The Growth Play
DNTH carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -67.3%, EPS growth -64.7%, 3Y rev CAGR -31.8%
- -67.1% 10Y total return vs BCAB's -99.8%
- -67.3% revenue growth vs BCAB's -81.8%
Best for: growth exposure and long-term compounding
BCAB
BioAtla, Inc.
The Income Pick
BCAB is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.36
- Lower volatility, beta 0.36, current ratio 0.37x
- Beta 0.36, current ratio 0.37x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  DNTH | -67.3% revenue growth vs BCAB's -81.8% |
| Quality / Margins | DNTH | -8.5% margin vs BCAB's -25.3% |
| Stability / Safety |  BCAB | Beta 0.36 vs DNTH's 1.29 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DNTH | +321.9% vs BCAB's -84.6% |
| Efficiency (ROA) | DNTH | -1.7% ROA vs BCAB's -309.4% |
DNTH vs BCAB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
DNTH vs BCAB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDNTHLAGGINGBCAB
BCABBioAtla, Inc.
1leads
DNTHDianthus Therapeutics…
2leads
6 Total Categories
CATEGORYLEADERvs BCABMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BCAB4/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DNTH4/4
Total Returns1Y, 3Y, 5Y total returns with dividends
DNTH6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BCAB leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
BCAB and DNTH operate at a comparable scale, with $2M and $1M in trailing revenue. DNTH is the more profitable business, keeping -8.5% of every revenue dollar as net income compared to BCAB's -25.3%.
| Metric | DNTHDianthus Therapeu… | BCABBioAtla, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $1M | $2M |
| EBITDAEarnings before interest/tax | -$191M | -$51M |
| Net IncomeAfter-tax profit | -$11M | -$51M |
| Free Cash FlowCash after capex | -$130M | -$23M |
| Gross MarginGross profit ÷ Revenue | +94.3% | +106.0% |
| Operating MarginEBIT ÷ Revenue | -143.2% | -25.2% |
| Net MarginNet income ÷ Revenue | -8.5% | -25.3% |
| FCF MarginFCF ÷ Revenue | -97.7% | -11.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -60.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -3.7% | +67.5% |
BCAB leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
Evenly matched — DNTH and BCAB each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | DNTHDianthus Therapeu… | BCABBioAtla, Inc. |
|---|---|---|
| Market CapShares × price | $3.2B | $4M |
| Enterprise ValueMkt cap + debt − cash | $3.1B | $4M |
| Trailing P/EPrice ÷ TTM EPS | -18.20x | -0.07x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1567.68x | 2.24x |
| Price / BookPrice ÷ Book value/share | 5.86x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — DNTH and BCAB each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
DNTH leads this category, winning 4 of 4 comparable metrics.
Profitability & Efficiency
| Metric | DNTHDianthus Therapeu… | BCABBioAtla, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -1.8% | — |
| ROA (TTM)Return on assets | -1.7% | -3.1% |
| ROICReturn on invested capital | -34.4% | — |
| ROCEReturn on capital employed | -41.6% | -4.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.00x | — |
| Net DebtTotal debt minus cash | -$50M | -$918,000 |
| Cash & Equiv.Liquid assets | $51M | $7M |
| Total DebtShort + long-term debt | $1M | $6M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
DNTH leads this category, winning 4 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
DNTH leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DNTH five years ago would be worth $4,126 today (with dividends reinvested), compared to $14 for BCAB. Over the past 12 months, DNTH leads with a +321.9% total return vs BCAB's -84.6%. The 3-year compound annual growth rate (CAGR) favors DNTH at 89.0% vs BCAB's -73.3% — a key indicator of consistent wealth creation.
| Metric | DNTHDianthus Therapeu… | BCABBioAtla, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +92.7% | -86.7% |
| 1-Year ReturnPast 12 months | +321.9% | -84.6% |
| 3-Year ReturnCumulative with dividends | +574.8% | -98.1% |
| 5-Year ReturnCumulative with dividends | -58.7% | -99.9% |
| 10-Year ReturnCumulative with dividends | -67.1% | -99.8% |
| CAGR (3Y)Annualised 3-year return | +89.0% | -73.3% |
DNTH leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — DNTH and BCAB each lead in 1 of 2 comparable metrics.
Risk & Volatility
BCAB is the less volatile stock with a 0.36 beta — it tends to amplify market swings less than DNTH's 1.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DNTH currently trades 79.2% from its 52-week high vs BCAB's 5.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DNTHDianthus Therapeu… | BCABBioAtla, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.29x | 0.36x |
| 52-Week HighHighest price in past year | $96.50 | $71.50 |
| 52-Week LowLowest price in past year | $16.64 | $0.33 |
| % of 52W HighCurrent price vs 52-week peak | +79.2% | +5.0% |
| RSI (14)Momentum oscillator 0–100 | 37.8 | 43.1 |
| Avg Volume (50D)Average daily shares traded | 674K | 44K |
Evenly matched — DNTH and BCAB each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates DNTH as "Buy" and BCAB as "Buy". Consensus price targets imply 6922.5% upside for BCAB (target: $250) vs 46.4% for DNTH (target: $112).
| Metric | DNTHDianthus Therapeu… | BCABBioAtla, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $111.91 | $250.00 |
| # AnalystsCovering analysts | 10 | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DNTH leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). BCAB leads in 1 (Income & Cash Flow). 2 tied.
Best OverallDianthus Therapeutics, Inc. (DNTH)Leads 2 of 6 categories
Loading custom metrics...
DNTH vs BCAB: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is DNTH or BCAB a better buy right now?
For growth investors, Dianthus Therapeutics, Inc.
(DNTH) is the stronger pick with -67. 3% revenue growth year-over-year, versus -81. 8% for BioAtla, Inc. (BCAB). Analysts rate Dianthus Therapeutics, Inc. (DNTH) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DNTH or BCAB?
Over the past 5 years, Dianthus Therapeutics, Inc.
(DNTH) delivered a total return of -58. 7%, compared to -99. 9% for BioAtla, Inc. (BCAB). Over 10 years, the gap is even starker: DNTH returned -67. 1% versus BCAB's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DNTH or BCAB?
By beta (market sensitivity over 5 years), BioAtla, Inc.
(BCAB) is the lower-risk stock at 0. 36β versus Dianthus Therapeutics, Inc. 's 1. 29β — meaning DNTH is approximately 257% more volatile than BCAB relative to the S&P 500.
04Which is growing faster — DNTH or BCAB?
By revenue growth (latest reported year), Dianthus Therapeutics, Inc.
(DNTH) is pulling ahead at -67. 3% versus -81. 8% for BioAtla, Inc. (BCAB). On earnings-per-share growth, the picture is similar: BioAtla, Inc. grew EPS 29. 9% year-over-year, compared to -64. 7% for Dianthus Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — DNTH or BCAB?
BioAtla, Inc.
(BCAB) is the more profitable company, earning -29. 8% net margin versus -79. 7% for Dianthus Therapeutics, Inc. — meaning it keeps -29. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BCAB leads at -29. 7% versus -87. 4% for DNTH. At the gross margin level — before operating expenses — DNTH leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — DNTH or BCAB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is DNTH or BCAB better for a retirement portfolio?
For long-horizon retirement investors, BioAtla, Inc.
(BCAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 36)). Both have compounded well over 10 years (BCAB: -99. 8%, DNTH: -67. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between DNTH and BCAB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.